BIOCORP Announces Partnership with AARDEX Group to Extend Smart Solutions for Precision Medication Adherence
01 Ottobre 2020 - 7:30AM
Business Wire
By combining their key technologies, both
companies offer innovative specific solutions for clinical trials
and numerous commercial applications
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME),
a French company specialized in the design, development and
manufacture of innovative medical devices, today announced an
alliance with Belgium-based AARDEX Group, the world leader in
medication adherence solutions.
This alliance is to combine BIOCORP’s connected add-on solutions
for drug delivery devices with AARDEX’s proprietary Medication
Event Monitoring System (MEMS®) and offer a comprehensive solution
to patients and healthcare providers to effectively measure and
manage medication adherence. The financial terms of the agreement
have not been disclosed, however the first initiative will be to
integrate BIOCORP’s Injay connected solution for Pre-filled
syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS®), to
target medicines delivered by PFS with potential applications in
the field of Rheumatoid Arthritis, Multiple Sclerosis,
Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap
also includes integration with BIOCORP’s other connected devices,
to cover further chronic conditions in the field of injectable,
respiratory, and beyond.
David Dalla Vecchia, CEO and Financial Lead of AARDEX Group,
said: "We are delighted to announce our partnership with BIOCORP.
Our vision is to continuously innovate in data-driven medication
adherence solutions to enhance digital therapeutics and patient
empowerment. Partnering with BIOCORP - a true pioneer in connected
devices - will significantly contribute to that objective and bring
together a wealth of knowledge and experience to help meet the
needs of today’s clinical trials, patients and healthcare
providers.”
Éric Dessertenne, CEO of BIOCORP, concluded: “This collaboration
with AARDEX Group brings a strong added value to our products and
to our targeted users. Thanks to the integration with MEMS AS, a
unique solution that analyzes deeply patient patterns and
behaviors, we will go beyond just monitoring treatment adherence,
by providing comprehensive and tailored solutions to boost
patient’s engagement and effectively manage this issue. AARDEX
specific expertise in clinical trials is also a strong asset and
will enable us to create relationships with pharma companies right
from the development stage of a drug”.
Medication adherence issues are well known by all healthcare
stakeholders and its clinical and commercial impact have been
quantified and heavily documented for many years now. The World
Health Organization has stated that, in developed countries,
adherence to long-term therapies in the general population is only
around 50%. But this issue is not limited to commercialized drugs
and real-life conditions, it also massively affects clinical
trials, which impacts assessment of drug efficacy.
ABOUT AARDEX GROUP
AARDEX Group is the world leader in digital solutions to measure
and manage medication adherence. Located in Belgium, in Switzerland
and in the U.S., AARDEX develops and markets digital solutions for
adherence-enhancing strategies in clinical trials, research
settings, and professional healthcare systems. AARDEX is the
central actor of a complete ecosystem that combines its MEMS®
Adherence Software with a wide range of smart packages and devices
that measure patient adherence across all routes of drug
administration. Our vision is to continuously innovate in
data-driven medication adherence solutions to enhance digital
therapeutics and patient empowerment.
For more information, visit www.aardexgroup.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture
of medical devices and delivery systems, BIOCORP has today acquired
a leading position in the connected medical device market thanks to
Mallya. This intelligent sensor for insulin injection pens allows
reliable monitoring of injected doses and thus offers better
compliance in the treatment of diabetics. Available for sale from
2020, Mallya spearheads BIOCORP's product portfolio of innovative
connected solutions. The company has 54 employees. BIOCORP is
listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more
information, please visit www.biocorpsys.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200930005883/en/
FOR MEDIA ENQUIRIES - ON BEHALF OF AARDEX GROUP Sophie
Beattie sophie@discovery-pr.com Mobile: + 44 (0) 7494 129 339
BIOCORP CONTACTS Jacques Gardette Chairman of the Board
investisseurs@biocorp.fr Éric Dessertenne Chief Executive Officer
Sylvaine Dessard Marketing & Communication Director
rp@biocorp.fr + 33 (0)6 88 69 72 85 ULYSSE COMMUNICATION
CONTACTS Bruno ARABIAN barabian@ulysse-communication.com +33
(0)6 87 88 46 26
Nicolas DANIELS ndaniels@ulysse-communication.com +33 (0)6 63 66
59 22
Grafico Azioni Biocorp (EU:ALCOR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Biocorp (EU:ALCOR)
Storico
Da Apr 2023 a Apr 2024